OBJECTIVE: Important differences between men and women with asthma have been demonstrated, with women describing more symptoms and worse asthma-related quality of life (QOL) despite having similar or better pulmonary function. While current guidelines focus heavily on assessing asthma control, they lack information about whether sex-specific approaches to asthma assessment should be considered. We sought to determine if sex differences in asthma control or symptom profiles exist in the well-characterized population of participants in the American Lung Association Asthma Clinical Research Centers (ALA-ACRC) trials. METHODS: We reviewed baseline data from four trials published by the ALA-ACRC to evaluate individual item responses to three standardized asthma questionnaires: the Juniper Asthma Control Questionnaire (ACQ), the multi-attribute Asthma Symptom Utility Index (ASUI), and Juniper Mini Asthma Quality of Life Questionnaire (mini-AQLQ). RESULTS: In the poorly-controlled population, women reported similar overall asthma control (mean ACQ 1.9 vs. 1.8; p = 0.54), but were more likely to report specific symptoms such as nocturnal awakenings, activity limitations, and shortness of breath on individual item responses. Women reported worse asthma-related QOL on the mini-AQLQ (mean 4.5 vs. 4.9; p < 0.001) and more asthma-related symptoms with a lower mean score on the ASUI (0.73 vs. 0.77; p ≤ 0.0001) and were more likely to report feeling bothered by particular symptoms such as coughing, or environmental triggers. CONCLUSIONS: In participants with poorly-controlled asthma, women had outwardly similar asthma control, but had unique symptom profiles on detailed item analyses which were evident on evaluation of three standardized asthma questionnaires.
OBJECTIVE: Important differences between men and women with asthma have been demonstrated, with women describing more symptoms and worse asthma-related quality of life (QOL) despite having similar or better pulmonary function. While current guidelines focus heavily on assessing asthma control, they lack information about whether sex-specific approaches to asthma assessment should be considered. We sought to determine if sex differences in asthma control or symptom profiles exist in the well-characterized population of participants in the American Lung Association Asthma Clinical Research Centers (ALA-ACRC) trials. METHODS: We reviewed baseline data from four trials published by the ALA-ACRC to evaluate individual item responses to three standardized asthma questionnaires: the Juniper Asthma Control Questionnaire (ACQ), the multi-attribute Asthma Symptom Utility Index (ASUI), and Juniper Mini Asthma Quality of Life Questionnaire (mini-AQLQ). RESULTS: In the poorly-controlled population, women reported similar overall asthma control (mean ACQ 1.9 vs. 1.8; p = 0.54), but were more likely to report specific symptoms such as nocturnal awakenings, activity limitations, and shortness of breath on individual item responses. Women reported worse asthma-related QOL on the mini-AQLQ (mean 4.5 vs. 4.9; p < 0.001) and more asthma-related symptoms with a lower mean score on the ASUI (0.73 vs. 0.77; p ≤ 0.0001) and were more likely to report feeling bothered by particular symptoms such as coughing, or environmental triggers. CONCLUSIONS: In participants with poorly-controlled asthma, women had outwardly similar asthma control, but had unique symptom profiles on detailed item analyses which were evident on evaluation of three standardized asthma questionnaires.
Keywords:
ACQ; ALA-ACRC; ASUI; ATAQ; American Lung Association Asthma Clinical Research Centers; Asthma; Asthma Control Questionnaire; Asthma Symptom Utility Index; Asthma Therapy Assessment Questionnaire; BMI; Control; Effectiveness of Low Dose Theophylline as Add-On Therapy In Treatment of Asthma; FEV(1); GERD; LOCCS; LODO; MID; PC(20); QOL; SABA; SARA; Sex differences; Study of Acid Reflux and Asthma; Symptom profiles; TAPE; Trial of Asthma Patient Education; body mass index; forced expiratory volume in one second; gastroesophageal reflux disease; leukotriene or corticosteroid or corticosteroid–salmeterol trial; mini asthma quality of life questionnaire; mini-AQLQ; minimal clinically important difference; provocative concentration of methacholine; quality of life; short-acting beta-agonist
Authors: Christian Bime; Christine Y Wei; Janet T Holbrook; Marianna M Sockrider; Dennis A Revicki; Robert A Wise Journal: J Allergy Clin Immunol Date: 2012-09-29 Impact factor: 10.793
Authors: W M Vollmer; L E Markson; E O'Connor; L L Sanocki; L Fitterman; M Berger; A S Buist Journal: Am J Respir Crit Care Med Date: 1999-11 Impact factor: 21.405
Authors: P Paoletti; L Carrozzi; G Viegi; P Modena; L Ballerin; F Di Pede; L Grado; S Baldacci; M Pedreschi; M Vellutini Journal: Am J Respir Crit Care Med Date: 1995-06 Impact factor: 21.405
Authors: Hanneke A H Wijnhoven; Didi M W Kriegsman; Frank J Snoek; Arlette E Hesselink; Marten de Haan Journal: J Asthma Date: 2003-04 Impact factor: 2.515
Authors: Ann-Kathrin Richter; Ludger Klimek; Hans F Merk; Norbert Mülleneisen; Harald Renz; Wolfgang Wehrmann; Thomas Werfel; Eckard Hamelmann; Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Janine Biermann-Stallwitz Journal: Eur J Health Econ Date: 2018-03-24
Authors: Francineide Lima Campos; Pedro Felipe Carvalhedo de Bruin; Thisciane Ferreira Pinto; Francisco Girleudo Coutinho da Silva; Eanes Delgado Barros Pereira; Veralice Meireles Sales de Bruin Journal: Sleep Breath Date: 2016-10-29 Impact factor: 2.816
Authors: Gretchen E White; Christen Seaman; Margaret S Filios; Jacek M Mazurek; Jennifer Flattery; Robert J Harrison; Mary Jo Reilly; Kenneth D Rosenman; Margaret E Lumia; Alicia C Stephens; Elise Pechter; Kathleen Fitzsimmons; Letitia K Davis Journal: J Asthma Date: 2014-03-27 Impact factor: 2.515
Authors: Jennifer A Kannan; David I Bernstein; Cheryl K Bernstein; Patrick H Ryan; Jonathan A Bernstein; Manuel S Villareal; Andrew M Smith; Peter H Lenz; Tolly G Epstein Journal: Ann Allergy Asthma Immunol Date: 2015-07-21 Impact factor: 6.347